Showing posts with label generic or biosimilar challengers. Show all posts
Showing posts with label generic or biosimilar challengers. Show all posts

Monday, March 13, 2023

The top 10 drugs losing US exclusivity in 2023; Fierce Pharma, March 13, 2023

Fraiser Kansteiner, Eric Sagonowsky, Zoey Becker, Kevin Dunleavy, Angus Liu, Fierce Pharma; The top 10 drugs losing US exclusivity in 2023

"Across the industry this year, big-selling drugs from Johnson & Johnson, Takeda, AstraZeneca, Roche and other companies are set to face their first generic or biosimilar challengers in the U.S. As always, the patent expirations should create quite a shake-up for many of the industry’s top players."